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Human T-cell lymphotropic virus (HTLV)-1 was the first human retrovirus to be associated 
to cancer, namely adult T-cell leukemia (ATL), but its pathogenesis remains enigmatic, 
since only a minority of infected individuals develops either ATL or the neuroinflammatory 
disorder HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). A 
functional FAS -670 polymorphism in an interferon (IFN)-regulated STAT1-binding site 
has been associated to both ATL and HAM/TSP susceptibility. Fashi T stem cell memory 
(Tscm) cells have been identified as the hierarchical apex of ATL, but have not been 
investigated in HAM/TSP. In addition, both FAS and STAT1 have been identified in an 
IFN-inducible HAM/TSP gene signature, but its pathobiological significance remains 
unclear. We comprehensively explored Fas expression (protein/mRNA) and function in 
lymphocyte activation, apoptosis, proliferation, and transcriptome, in PBMC from a total 
of 47 HAM/TSP patients, 40 asymptomatic HTLV-1-infected individuals (AC), and 58 
HTLV-1 -uninfected healthy controls. Fas surface expression followed a two-step increase 
from HC to AC and from AC to HAM/TSP. In HAM/TSP, Fas levels correlated positively to 
lymphocyte activation markers, but negatively to age of onset, linking Fashi cells to earlier, 
more aggressive disease. Surprisingly, increased lymphocyte Fas expression in HAM/
TSP was linked to decreased apoptosis and increased lymphoproliferation upon in vitro 
culture, but not to proviral load. This Fashi phenotype is HAM/TSP-specific, since both ex 
vivo and in vitro Fas expression was increased as compared to multiple sclerosis (MS), 
another neuroinflammatory disorder. To elucidate the molecular mechanism underlying 
non-apoptotic Fas signaling in HAM/TSP, we combined transcriptome analysis with 
functional assays, i.e., blocking vs. triggering Fas receptor in vitro with antagonist and 
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KeY POinTs
• A two-step increase in cell death receptor Fas occurs upon 
HTLV-1 infection and disease progression.
• Unexpectedly, higher Fas level was linked to decreased cell 
death, increased lymphocyte proliferation/activation, and 
early disease onset.
inTrODUcTiOn
Human T-cell lymphotropic virus 1 (HTLV-1) is an exogenous 
human retrovirus infecting 5–10 million people worldwide, 
mostly in HTLV-1 endemic regions (1). While a majority of 
HTLV-1 carriers remain asymptomatic (AC) lifelong, a minority 
(0.25–3%) progresses to either adult T-cell leukemia/lymphoma 
(ATL) or HTLV-1-associated myelopathy/tropical spastic para-
paresis (HAM/TSP) (2, 3). Thirty years after its discovery, it is still 
enigmatic how a single retrovirus causes either fatal hematologic 
malignancy or neuroinflammation in a small subset of infected 
individuals. Among factors that allow to discriminate between 
the three clinical groups (AC, ATL, and HAM/TSP), humoral 
immunity (4) and the proteome (5, 6) have been described. In 
agreement with a role for immune activation (4, 6–9) in HAM/
TSP pathogenesis, promising preclinical results were obtained 
with Jak kinase and NFκB inhibitors (10, 11). Very few drugs, 
e.g. valproate, have actually overcome the hurdle in transition 
from preclinical results (12) to clinical trial in HAM/TSP (13). 
Taken together, these studies point at a possible clinical benefit 
of decreasing lymphoproliferation and/or increasing apoptosis 
in HAM/TSP patients. HTLV-1-infected cells are driven toward 
spontaneous lymphoproliferation and oligoclonal expansion 
(14, 15). On the other hand, apoptosis (programmed cell death) 
is known to play a role in controlling lymphoproliferation in 
autoimmune diseases (16, 17). Fas (TNFRSF6/CD95/APO-1) 
is a death-domain-containing receptor of the tumor necrosis 
factor (TNF) receptor superfamily inducing apoptosis (17), 
when ligated by Fas ligand (FasL) or agonist antibodies (18). 
Fas-FasL signaling is proposed to play a role in both autoim-
mune and infectious diseases (17). In multiple sclerosis (MS) 
patients, increased Fas expression has since long been known 
(19), while resistance of T cells to Fas-mediated apoptosis has 
been linked to MS (20). In HTLV-1 infection, a wealth of data is 
available on pro- and anti-apoptotic effects of HTLV-1 infection, 
mainly its proto-oncogene tax (21). In the context of HAM/TSP 
immunopathogenesis, a role for Fas-FasL in the downregula-
tion of immune response in the CNS has been suggested (22). 
Previous studies on Fas in HAM/TSP have shown increased 
levels of soluble Fas in serum (23, 24), and CSF (24), as well as 
surface expression in CD8 cells (25). A systems biology approach 
identified FAS (but not FASL) as a part of an interferon (IFN)-
regulated gene signature in HAM/TSP patients (7). In addition, 
immunogenetic data revealed that a functional FAS -670 gene 
polymorphism is associated to both ATL (26) and HAM/TSP 
(27) disease susceptibility. Therefore, we hypothesized that 
lymphocyte Fas expression and/or apoptosis may reflect clinical 
status in HAM/TSP patients.
PaTienTs anD MeThODs
A flow chart diagram (Figure  1) provides an overview of the 
study outline, cohorts, as well as ex vivo, in  vitro, and in  silico 
experimental approach, while patient information and sample 
use is summarized in Table 1.
HAM/TSP patients [n  =  47, 66.0% female, mean age 
50.2 ± 11.5 years, mean disease duration 5.6 ± 4.0 years (range 
0.8–14 years), EDSS range 3–7 (mean 5.1 ± 1.2)] were recruited 
from three endemic regions (Sao Paulo and Salvador, Bahia, 
Brazil, and Lima, Peru) following written informed consent. 
Age- and gender-matched HTLV-1-infected asymptomatic car-
riers (AC, n = 40) and uninfected healthy controls (HC, n = 58) 
from the same endemic regions were included in the study. The 
study was approved by the Ethics Committees of University of Sao 
Paulo and FIOCRUZ-Bahia in Brazil and Universidad Peruana 
Cayetano Heredia in Lima, Peru. Diagnosis of HAM/TSP was 
according to WHO criteria (28) Antibodies to HTLV-1/2 were 
investigated by diagnostic ELISA (Murex, Abbott, Germany; 
Bioelisa HTLV-1 + 2, Biokit Spain) and confirmed by Western 
blot capable of discriminating between HTLV-1 and HTLV-2 
(HTLV Blot 2.4, Genelab, Singapore). All HTLV-1-infected indi-
viduals were seronegative for HTLV-2 and HIV. For comparison 
with another neuroinflammatory disorder, data from MS patients 
[recruited during our previous study (29)] were used.
agonist-, anti-Fas mAb, respectively. Treatment with agonist anti-Fas mAb restored 
apoptosis, indicating biased, but not defective Fas signaling in HAM/TSP. In silico 
analysis revealed biased Fas signaling toward proliferation and inflammation, driven by 
RelA/NF-κB. Correlation of Fas transcript levels with proliferation (but not apoptosis) 
was confirmed in HAM/TSP ex vivo transcriptomes. In conclusion, we demonstrated 
a two-step increase in Fas expression, revealing a unique Fashi lymphocyte phenotype 
in HAM/TSP, distinguishable from MS. Non-apoptotic Fas signaling might fuel HAM/
TSP pathogenesis, through increased lymphoproliferation, inflammation, and early age 
of onset.
Keywords: Fas/cD95, proliferation, hTlV-1-associated myelopathy/tropical spastic paraparesis, 
lymphoproliferative disease, apoptosis, interferon, nF-κB, multiple sclerosis
FigUre 1 | schematic representation of the methodology (ex vivo, in vitro, and in silico approaches).
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isolation of PBMc and In Vitro cell culture
PBMC isolated from 5–10  ml of heparinized venous blood by 
Ficoll–Hypaque density gradient centrifugation (Sigma-Aldrich) 
were washed twice with PBS and were plated in 24-well tissue 
culture plates (Costar, NY, USA) at 4 ×  106  cells/ml and incu-
bated at 37°C and 5% CO2 in RPMI1640 medium supplemented 
with 2mM l-glutamine, gentamycin (50 µg/ml), and 10% heat-
inactivated fetal calf serum (Gibco, NY, USA).
hTlV-1 p19 and Proviral load 
Quantification
Human T-cell lymphotropic virus-1 matrix protein p19 was 
quantified in cell-free supernatant of HAM/TSP patients’ PBMC 
and AC and HC using RetroTek HTLV-1/2 p19 Antigen ELISA 
kit (ZeptoMetrix) after 48 h of in vitro culture. Proviral load (PVL, 
i.e., viral DNA integrated into the host genome) in HAM/TSP 
patients and AC was quantified as published (30, 31).
Quantification of cell surface Markers by 
Flow cytometry
For phenotypic analysis, PBMC were resuspended at a density of 
200,000 cells in 50 µl of 1% BSA, 0.1% NaN3 in PBS (+20% human 
serum to block Fc receptors), and incubated for 30 min on ice with 
mAbs specific for CD3, CD4, CD8, CD80, CD86, CD95/Fas, and 
HLA-DR and corresponding isotype controls (BD Biosciences). 
For total Fas surface quantification and apoptosis, a minimum of 
100,000 events/sample were stained and acquired with FACSort 
and FACSCanto II flow cytometers (BD Biosciences) and ana-
lyzed using CellQuest and Diva software, respectively.
Proliferation and apoptotic assays
Lymphoproliferation was quantified by [3H]-thymidine incor-
poration and flow cytometry [as described in Ref (29, 32)], the 
initial stage of apoptosis was analyzed using annexin V staining, 
whereas cells in the late/final stage of apoptosis were identified as 
a sub-diploid population by flow cytometry. Nuclear fragmenta-
tion was quantified by fluorescence microscopy and ELISA (Cell 
Death Detection plus, Boehringer Mannheim, Germany).
Fas Triggering and Blocking experiments
PBMC were cultured as above for 48  h in the presence or 
absence of agonist or antagonist anti-Fas mAbs (1 µg/ml, Alexis 
Biochemicals) or anti-CD3 mAb (Butantan Institute, Sao Paulo, 
Brazil) as a positive control for in vitro apoptosis.
Microarray analysis
Total RNA was extracted from PBMC according to manufactur-
er’s protocol (QIAgen, Venlo, The Netherlands). Whole genome 
microarray was performed at VIB Nucleomics (Leuven, Belgium) 
using GeneChip® Human Gene1.0 ST Array (Affymetrix, Santa 
Clara, CA, USA), according to manufacturer’s specifications. 
Data were analyzed using Bioconductor limma package, using 
TaBle 1 | Patient information and sample use.
Patient age gender cohort analysis
1 NA F BA Ex vivo flow cytometry
2 NA M BA Ex vivo flow cytometry
3 NA F BA Ex vivo flow cytometry
4 NA F BA Ex vivo flow cytometry
6 NA F BA Ex vivo flow cytometry
7 51 M BA Ex vivo and in vitro flow cytometry, in vitro apoptosis, in vitro lymphoproliferation
8 40 M BA Ex vivo flow cytometry, in vitro apoptosis, in vitro lymphoproliferation
9 40 F BA Ex vivo flow cytometry, in vitro apoptosis, in vitro lymphoproliferation
10 63 F BA Ex vivo flow cytometry, in vitro apoptosis, in vitro lymphoproliferation
11 51 F BA Ex vivo and in vitro flow cytometry, in vitro apoptosis, in vitro lymphoproliferation
12 36 M BA Ex vivo and in vitro flow cytometry, in vitro apoptosis, in vitro lymphoproliferation
13 40 F BA Ex vivo and in vitro flow cytometry, in vitro apoptosis, in vitro lymphoproliferation
14 60 F BA Ex vivo and in vitro flow cytometry, in vitro apoptosis, in vitro lymphoproliferation
15 44 M BA Ex vivo flow cytometry, in vitro apoptosis, in vitro lymphoproliferation
16 NA F BA Ex vivo flow cytometry, in vitro apoptosis, in vitro lymphoproliferation
17 53 M BA Ex vivo and in vitro flow cytometry, in vitro apoptosis, in vitro lymphoproliferation, microarray
18 45 F BA Ex vivo and in vitro flow cytometry, in vitro apoptosis, in vitro lymphoproliferation, microarray
20 59 M BA Ex vivo and in vitro flow cytometry, in vitro apoptosis, in vitro lymphoproliferation
21 60 F BA Ex vivo and in vitro flow cytometry, in vitro apoptosis, in vitro lymphoproliferation
22 38 M BA In vitro lymphoproliferation
23 59 F BA In vitro lymphoproliferation
24 56 F BA In vitro flow cytometry, in vitro apoptosis, in vitro lymphoproliferation, microarray
25 49 F BA In vitro apoptosis
26 57 M BA In vitro apoptosis
27 49 F BA In vitro flow cytometry, in vitro apoptosis in vitro lymphoproliferation
28 60 M BA In vitro flow cytometry, in vitro apoptosis in vitro lymphoproliferation, microarray
29 46 M BA In vitro apoptosis, in vitro lymphoproliferation, microarray
31 50 M BA In vitro flow cytometry, in vitro apoptosis, in vitro lymphoproliferation, microarray
32 50 F BA In vitro flow cytometry, in vitro apoptosis, in vitro lymphoproliferation, microarray
33 62 F BA In vitro flow cytometry, in vitro apoptosis, in vitro lymphoproliferation
2,569 27 F LI In vitro apoptosis
2,570 50 F LI In vitro apoptosis
2,574 35 F LI In vitro apoptosis
2,817 64 F LI Ex vivo flow cytometry
2,819 32 F LI Ex vivo flow cytometry
2,821 63 F LI Ex vivo flow cytometry
2,822 50 F LI Ex vivo flow cytometry
2,823 64 M LI Ex vivo flow cytometry
SP5 32 F SP Ex vivo flow cytometry
SP6 65 F SP Ex vivo flow cytometry
SP7 62 F SP Ex vivo flow cytometry
SP8 47 F SP Ex vivo flow cytometry
SP26 35 M SP Ex vivo flow cytometry
SP30 72 M SP Ex vivo flow cytometry
SP32 27 M SP Ex vivo flow cytometry
SP36 52 F SP Ex vivo flow cytometry
SP46 61 F SP Ex vivo flow cytometry
Cohorts: BA, Bahia; LI, Lima; SP, Sao Paulo.
NA, not available.
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FigUre 2 |  Ex vivo lymphocyte Fas surface expression in hTlV-1-infected individuals (ac), haM/TsP, and multiple sclerosis (Ms) patients. Using flow 
cytometry, Fas levels as % (a) and mean fluorescence intensity (MFI, on a per cell basis) (B) were quantified in HC, AC, and HAM/TSP patients (*p < 0.05, 
**p < 0.01, ***p < 0.001; Kruskal–Wallis, with Dunn’s multiple comparison post-test). (c) Fas expression in CD4, CD8, and B cells was quantified in ex vivo PBMC in 
HC, AC, and HAM/TSP patients (ANOVA, p = 0.067, post-test for linear trend p < 0.05). (D) Ex vivo Fas levels (% and MFI) are compared between 
neuroinflammatory diseases HAM/TSP and MS (Mann–Whitney test, *p < 0.05).
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a moderated t-test, resulting p-values were corrected for genome-
wide testing (5% FDR). All microarray raw data are available at 
Gene Expression Omnibus database (GEO, http://www.ncbi.nlm.
nih.gov/geo/) series accession number GSE82160.
statistical analysis
The use of parametric (t-test, Pearson correlation) or non-
parametric (Mann–Whitney or Spearman rank correlation) 
tests was based on normal distribution as determined by 
Kolmogorov–Smirnov test (all GraphPad Prism v5.0 or v6.0). 
A p-value of <0.05 was considered significant for all statistical 
tests. Transcriptome-wide correlation of FAS mRNA expression 
levels was calculated using Spearman rank correlation test, with 
stringent correction for multiple testing (5% FDR).
resUlTs
a Two-step increase in Ex Vivo Total 
lymphocyte Fas surface expression in 
hTlV-1-infected individuals and haM/TsP 
Patients, Distinguishable from Ms Patients
In a first cohort, we quantified surface Fas levels as well as apop-
tosis by flow cytometry, ex vivo in PBMC from HC (HTLV-1-
negative, n = 14), AC (HTLV-1-positive, n = 30), and HAM/TSP 
patients (n = 18). We observed a significant increase in ex vivo 
levels (%) of Fas+ lymphocyte in AC (1.8-fold) as well as in HAM/
TSP patients (2.1-fold), when compared to HC (Kruskal–Wallis, 
Dunn’s posttest, p <  0.05, p <  0.001, respectively, Figure  2A). 
Moreover, lymphocyte Fas level on a per-cell basis, expressed 
as mean fluorescence intensity (MFI), revealed an eight-fold 
increase in AC and a striking 19-fold increase in HAM/TSP 
(Kruskal–Wallis, Dunn’s post-test, p <  0.001), when compared 
to HC, but also when compared to AC (p <  0.05, Figure  2B), 
indicating that clinical progression to HAM/TSP is characterized 
by a predominant Fashi lymphocyte population, possibly primed 
for apoptosis. To confirm the two-step model of Fas increase, we 
performed a post hoc test for linear trend, which was highly sig-
nificant (p < 0.001) for both % (slope 18.8) and MFI (slope 64.1).
Next, we proceeded to examine Fas expression in CD4, CD8, 
and B cell subsets in more detail in an independent second cohort 
of HC (n =  7), AC (n =  6), and HAM/TSP patients (n =  9). 
There was no difference in the percentage of cells expressing 
Fas between the three clinical groups for either cellular subset 
(Figure 2C). However, we observed a small but significant linear 
trend in Fas MFI of CD4+ T cells with clinical status (ANOVA 
p = 0.067, post-test for linear trend p < 0.05, slope 349.2), but 
not in CD8+ T cells or B cells. Thus, the strongest difference 
between the clinical groups was in total Fas+ lymphocytes rather 
than specific subsets, revealing a Fashi phenotype in HAM/TSP. 
FigUre 3 | increased ex vivo lymphocyte Fas surface expression in haM/TsP patients correlates with activation markers. Positive correlation between 
the percentage of Fas+ lymphocytes and (a) HLA-DR+ (*p = 0.039, Spearman’s r = 0.56, n = 14) and (B) CD86+ (*p = 0.031, Spearman’s r = 0.60, n = 13) 
lymphocytes in HAM/TSP patients.
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To verify if this Fashi phenotype might be shared among neuro-
inflammatory disorders, we compared Fas expression between 
HAM/TSP and MS patients. As shown in Figure 2D, we found 
a significant 1.6-fold increase in % of ex vivo Fas+ lymphocytes 
in HAM/TSP (Mann–Whitney, p = 0.03), as well as a 2.4-fold 
increase in Fas MFI, which approached statistical significance 
(Mann–Whitney, p = 0.08).
Finally, ex vivo spontaneous apoptosis in HAM/TSP and AC, 
as measured by DNA degradation (quantified as sub-diploid 
cells in flow cytometry) occurred at very low levels (<0.2% of 
PBMC, data not shown). Therefore, we questioned if the observed 
ex vivo increase in lymphocyte Fas surface expression in HAM/
TSP reflected the immunological, virological, or clinical status of 
HAM/TSP patients, rather than an apoptosis-prone status.
Ex Vivo lymphocyte Fas surface 
expression correlates to immune 
activation Markers in haM/TsP
To explore possible clinical relevance of this increased lym-
phocyte Fas in HAM/TSP patients, we correlated ex vivo Fas 
surface expression to patient demographic and clinical data. We 
observed that, in HAM/TSP, ex vivo lymphocyte Fas (% or MFI) 
was not correlated to age, gender, disease duration, or severity. 
In addition, ex vivo lymphocyte Fas was not significantly cor-
related to PVL in AC or HAM/TSP (p > 0.05). However, ex vivo 
Fas levels (%) correlated significantly to lymphocyte activation 
markers HLA-DR and CD86 (Figures  3A,B), implying that 
increased Fas expression may be coupled to immune activation 
and/or inflammation in HAM/TSP.
In Vitro Fas+ lymphocyte levels 
correlate negatively to Both age 
of Onset and In Vitro apoptosis:  
a selective Defect in haM/TsP Patients?
Upon quantification of in vitro Fas+ lymphocyte expression in 
HC, AC, and HAM/TSP patients by flow cytometry, we again 
observed a two-step increase in % Fas+ lymphocytes: two-fold 
in AC and 3.4-fold in HAM/TSP vs. HC (post-test for linear 
trend, p = 0.0001, slope 27.0) (Figure 4A). In HAM/TSP, in vitro 
Fas levels per-cell (MFI) were even more pronounced, with an 
eight-fold increase over HC. Hence, clinical status impacts both 
ex vivo (Figures 2A,B) and in vitro (Figure 4A) Fas expression. 
In addition, Fas in vitro levels showed a significant negative cor-
relation to age of disease onset in HAM/TSP patients (p = 0.019, 
Pearson’s r = −0.69, n = 11) (Figure 4B), but not to age, disease 
duration, and gender, suggesting Fashi phenotype predisposes 
to earlier, aggressive disease manifestation. Further, in  vitro 
Fas expression neither correlated to viral p19 protein level 
(p = 0.41), nor to PVL (p = 0.14) in HTLV-1-infected individu-
als (data not shown).
In agreement with its role as a death receptor in immune 
homeostasis, Fas surface expression positively correlates with 
spontaneous in vitro apoptosis in HC, while this correlation was 
lost in AC (data not shown). Surprisingly, ex vivo Fas expression 
correlated negatively (Figure S1 in Supplementary Material) 
to spontaneous in  vitro apoptosis in HAM/TSP. Furthermore, 
in vitro Fas level (MFI) also correlates negatively to lymphocyte 
apoptosis in HAM/TSP (Figure 5A). This negative correlation was 
confirmed by fluorescence microscopy. As shown in Figure 5B, 
Fashi cells are negative for annexin V staining and display normal 
nuclear morphology, whereas Faslo cells were seen to undergo 
apoptosis by both annexin V staining and nuclear condensation/
fragmentation, occasionally triggering phagocytosis by mac-
rophages, emphasizing their apoptotic nature. Since resistance to 
Fas induced apoptosis has been observed in vitro in lymphocytes 
from MS patients (33), we compared in  vitro lymphocyte Fas 
expression and apoptosis between HAM/TSP and MS patients. 
As shown in Figure 5C, there was a significant increase (2.4-fold, 
Mann–Whitney test, p = 0.019) in Fas MFI in HAM/TSP as com-
pared to MS patients, but not apoptosis (as measured by annexin 
V staining, Mann–Whitney test, p = 0.84). In contrast to HAM/
TSP, no correlation was observed between Fas MFI and apoptotic 
cells in MS patients (p = 0.35, data not shown). Taken together, 
FigUre 4 | significant linear trend in Fas+ lymphocyte levels in PBMc of hc, ac, and haM/TsP patients upon in vitro culture, and negative 
correlation with age of onset of haM/TsP. (a) Fas levels were quantified by flow cytometry after 48 h of in vitro culture. Fas+ lymphocytes (%) gradually increase 
(HC: n = 12; AC: n = 4; HAM: n = 12) upon infection (AC) and further upon disease progression to HAM/TSP (ANOVA, p = 0.0005; posttest for linear trend, 
p < 0.0001). (B) Lymphocyte Fas levels (after 48 h of in vitro culture) quantified by flow cytometry (MFI) correlate negatively to age of onset in HAM/TSP patients 
(*p = 0.019, Pearson’s r = −0.69, n = 11).
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the significant negative correlations between ex vivo and in vitro 
Fas lymphocyte expression and in vitro apoptosis observed only 
in HAM/TSP, suggest a possible selective defect in Fas-mediated 
apoptosis. Hence, we next aimed to comprehensively explore 
non-apoptotic Fas signaling in HAM/TSP.
Fas expression Positively correlates 
to lymphoproliferation In Vitro and  
Ex Vivo in haM/TsP
We quantified in  vitro spontaneous lymphoproliferation by 
[3H]-thymidine incorporation in HAM/TSP patients. Surpri-
singly, we found that Fas expression positively correlates to 
spontaneous lymphoproliferation in  vitro (Figure  6A), which 
might imply that the observed defect in Fas-mediated proapop-
totic signaling in HAM/TSP might be explained as a bias in Fas 
signaling toward proliferation rather than apoptosis. Therefore, 
we hypothesized that Fashi cells might be already proliferat-
ing in vivo in HAM/TSP although at a very low level. We thus 
extended our previously described (29) sensitive flow cytometry 
assay to quantify Fas+ diploid vs. tetraploid (proliferating) lym-
phocytes ex vivo in HAM/TSP patients, stained immediately after 
PBMC isolation, without in vitro culture. As shown in Figure 6B, 
virtually all of the proliferating cells were Fashi (99.2 ± 0.8%), as 
compared to non-proliferating lymphocytes (69.4 ± 5.9%, Paired 
t-test, p = 0.0082).
stimulation with agonist Fas mab  
In Vitro can Trigger apoptotic signaling 
in haM/TsP
We then examined if this apparent defect in Fas-mediated apop-
tosis might be reversible by stimulating with agonist anti-Fas 
mAb, and if blocking with antagonist anti-Fas mAb could reveal 
ongoing Fas-FasL signaling in HAM/TSP. Hence, we treated 
PBMC in  vitro with anti-Fas mAb (agonist or antagonist) or 
anti-CD3 mAb as a positive control. No decrease in spontaneous 
apoptosis was observed upon treatment with antagonist anti-Fas 
mAb, confirming our hypothesis of inactive Fas-FasL signaling 
in vitro in HAM/TSP. Interestingly, treatment with agonist anti-
Fas mAb resulted in significantly increased apoptosis (1.7-fold, 
p <  0.05), similar to treatment with anti-CD3 mAb (positive 
control, 1.8-fold, p < 0.01) (Figure 7A). These results imply that 
agonist anti-Fas mAb treatment can restore the apparent defect 
in apoptosis in HAM/TSP, at least in vitro.
systems analysis of gene expression 
Profiles Upon Fas Triggering vs. Fas 
Blocking in haM/TsP
Considering the significant correlation between in  vitro Fas 
expression to age of onset in HAM/TSP, we resorted to genome-
wide transcriptional analysis of PBMC treated in vitro with agonist 
or antagonist Fas mAb, to explore the broad pro/antiapoptotic, 
inflammatory, proliferative, and immunoregulatory Fas signal-
ing pathways specifically triggered in HAM/TSP. Microarray 
analysis revealed that in  vitro treatment with agonist anti-Fas 
mAb, significantly downregulated 190 genes and upregulated 
59 genes (Tables S1A,B in Supplementary Material), while treat-
ment with antagonist anti-Fas mAb downregulated 38 genes and 
upregulated 18 genes (Tables S1C,D in Supplementary Material). 
Thus, triggering Fas signaling effects a broader gene spectrum 
than inhibiting it. This was also evident from Ingenuity® pathway 
analysis (IPA), since no biological functions were significantly 
associated with antagonist anti-Fas mAb treatment, whereas 
treatment with agonist anti-Fas mAb resulted in 22 significantly 
associated biological functions (5% FDR-adjusted and a stringent 
cut-off of at least five enriched molecules per pathway) (Table 
S2 in Supplementary Material). The top 10 biological functions 
FigUre 5 | Fashi cells are apoptosis-resistant in haM/TsP patients. (a) Fas mean fluorescence intensity (MFI, on a per-cell basis) negatively correlates to 
apoptosis (quantified as % annexin V+ cells) in lymphocytes of HAM/TSP patients (*p = 0.012, Spearman’s r = −0.63, n = 15). (B) In the middle panel is a 
representative image of a non-apoptotic Fashi cell (indicated by a white horizontal arrow). This Fashi cell is annexin V negative as visualized in the first panel and 
displays a normal nuclear morphology seen in the third panel. On the contrary, a Faslo cell in panel 2 (black vertical arrow), displays pronounced annexin V staining 
(panel 1) and is undergoing apoptosis, as evidenced by nuclear condensation, and is being engulfed by a macrophage (panel 3). (c) In vitro Fas levels (MFI) and 
apoptosis (% of Annexin V+ cells) are compared between neuroinflammatory diseases HAM/TSP and multiple sclerosis (Mann–Whitney test, *p < 0.05).
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activated by agonist anti-Fas mAb (Table S2 in Supplementary 
Material), highlight cellular migration, especially of myeloid 
cells. In addition, IPA network analysis (Figure  7B) of Fas-
triggered gene expression reveals a central role for NFκB pro-
survival signaling, connecting several upregulated proliferative 
and inflammatory molecules (TNF, JNK, RNA Polymerase II, 
POLR2D, HIST1H3A, HIST1H2AB) as well as downregulated 
anti-proliferative genes (L3MBTL2, CARD6). This central role 
for NFκB signaling was confirmed by ingenuity upstream regu-
lator analysis, identifying RelA as the top upstream regulatory 
molecule upon triggering Fas signaling (target genes: BCL2A1, 
CASR, CXCL3, ICAM1, L3MBTL2, PTGES, TGM2, TNF, and 
TPMT; p =  0.000032). Again, blocking Fas signaling did not 
yield any significantly enriched upstream regulators (using the 
same stringent cut-off of five enriched molecules/pathway, data 
not shown).
genome-Wide correlation of Ex Vivo Fas 
rna levels in haM/TsP confirms a 
significant association to Proliferation but 
not apoptosis
Finally, we used a pathway-based data mining approach, to test 
our hypothesis of biased Fas signaling, and to possibly extend 
our findings by including additional pro- and anti-apoptotic 
genes (e.g., TRAIL, cFlip, etc.). For this purpose, we explored 
FigUre 7 |  In vitro Fas triggering with agonist anti-Fas mab induces apoptosis in haM/TsP and activates a molecular network linking apoptosis, 
proliferation and inflammation. (a) Agonist (ago) anti-Fas mAb, but not antagonist (ant) anti-Fas mAb increased apoptosis (quantified by CellDeathPlus ELISA) in 
PBMC upon in vitro treatment for 24 h when compared to control (untreated) PBMC. Treatment with anti-CD3 mAb was used as a positive control (ANOVA, with 
Bonferroni’s post-test *p < 0.05, **p < 0.01). (B) Top molecular network (score = 34, linking cell-to-cell signaling, interaction, and cellular growth and proliferation) 
identified by Ingenuity pathway analysis (IPA) among 249 genes significantly up- and downregulated (red and green, respectively) in PBMC of HAM/TSP patients by 
in vitro treatment with agonist anti-Fas mAb.
FigUre 6 | Fas surface expression correlates positively with in vitro 
and ex vivo lymphoproliferation in haM/TsP patients. (a) In vitro Fas 
expression as measured by flow cytometry (MFI) correlates positively to 
lymphoproliferation quantified by [3H]-thymidine incorporation (*p = 0.018, 
Pearson’s r = 0.62, n = 14). (B) Ex vivo Fas surface expression measured by 
flow cytometry (% and MFI) is significantly higher in proliferating (tetraploid, 
4n) cells vs. diploid (2n) cells in HAM/TSP patients (paired t-test, **p = 0.0082 
and **p = 0.0023, respectively, n = 5).
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possible interactions of Fas mRNA within the ex vivo global 
gene expression profile in PBMC of HAM/TSP patients (n = 6). 
Using transcriptome-wide correlation, 4,554 genes significantly 
correlated to Fas transcript levels (Table S3 in Supplementary 
Material), after stringent FDR-correction for multiple testing. 
Using annotated ingenuity pathways, we found a significant 
enrichment for proliferation-related genes (159 of 4,554 genes, 
p  =  0.023). However, apoptosis, as defined by IPA, was not 
enriched amongst the ex vivo Fas-correlating genes (71 genes out 
of 4,554 genes, p = 0.10).
DiscUssiOn
In this study, we combined ex vivo, in vitro, and systems analysis 
of Fas expression with functional apoptosis and proliferation 
assays, thereby providing an all-inclusive approach of the bio-
logical and clinical relevance of Fas signaling in HAM/TSP. We 
observed a two-step increase in ex vivo Fas expression: first, a 
greater percentage of Fas+ lymphocytes upon HTLV-1 infection 
and second, a strong increase in expression of the death receptor 
at the single-cell level upon HAM/TSP disease progression. In 
addition, for the first time, we demonstrate that Fas expression 
correlates negatively to apoptosis and age of onset, but positively 
to immune activation and lymphoproliferation.
The most surprising finding of this study is a selective defect in 
Fas-mediated apoptosis in HAM/TSP patients. First, both ex vivo 
and in vitro Fas levels negatively correlated to in vitro apoptosis 
(Figure  5A; Figure S1 in Supplementary Material). Second, by 
fluorescence microscopy (Figure  5B), we document that Faslo, 
but not Fashi cells, preferentially undergo apoptosis in  vitro. 
Third, in  vitro treatment of PBMC with agonist anti-Fas mAb, 
but not antagonist anti-Fas mAb, was able to trigger apoptosis 
and restore the selective defect in HAM/TSP patients. Fourth, 
in  silico analysis of the HAM/TSP transcriptome revealed a 
large number of transcripts (>4,500) significantly correlating to 
FigUre 8 | Model indicating the two-step increase in ex vivo lymphocyte Fas surface expression. First, following human T-cell lymphotropic virus (HTLV)-1 
infection, there is an increase in lymphocyte Fas expression (%) in AC. Second, upon progression to HAM/TSP, Fas expression is increased on a per-cell basis as 
mean fluorescence intensity (MFI) (Figures 2a,B). In agreement with its role as a death receptor, Fas+ cells in HC are primed to follow the apoptotic pathway, 
depicting nuclear condensation and cell blebbing, which is lost upon HTLV-1 infection (AC). In contrast, in HAM/TSP patients, Fashi cells are driven toward 
proliferation (Figures 6a,B). We recently discovered a genotype/phenotype interaction for the FAS -670 polymorphism with both apoptosis and proliferation in adult 
T-cell leukemia (ATL) patients and healthy controls (Khouri et al., submitted). This Fashi proliferating and chemotherapy-resistant leukemic phenotype is in agreement 
with the recently discovered CD4 T stem cell memory (Tscm) hierarchical apex of ATL. The same FAS -670 polymorphism also determined CD4 Tscm levels in a 
genome-wide twin study, confirming our hypothesis (Khouri et al., submitted). Therefore, a genetically determined interferon (IFN)/STAT1/FAS axis might help explain 
the proliferative, non-apoptotic phenotype in HAM/TSP suggesting CD4 Tscm as a pivotal factor not only in ATL but also in HAM/TSP pathogenesis. Considering 
STAT1 and FAS are in the HAM/TSP gene signature, our data further refine the data of Tattermusch et al. (7) It is not unexpected that a Tscm phenotype is absent 
from the disease signature, since Tscm are rare (2–3%) (45) and their genome-wide expression profile is intermediate between naïve and central memory T cells. 
However, Tscm cells have a Fashi, apoptosis-resistant, and drug-resistant, proliferative phenotype, in agreement with their stem cell-like nature. Interestingly, the 
proliferating cells in HAM/TSP patients were almost exclusively Fashi (Figure 6B), compatible with a Tscm phenotype.
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Fas mRNA level, but are not enriched for apoptotic pathways. 
Taken together, our data indicate that the death receptor is fully 
functional in HAM/TSP, and not in a dormant state, but skewed 
towards other biological pathways. Similar to our observation 
in HAM/TSP, increased Fas (19) and resistance to Fas-triggered 
apoptosis (34) has been reported in MS, which was also supported 
by gene expression profiling (35). Nevertheless, our data reveal 
that the Fashi phenotype is HAM/TSP-specific, since Fas expres-
sion was increased both ex vivo and in vitro, as compared to MS 
patients. Strikingly, the increase in non-apoptotic Fas receptor is 
also negatively correlated to age of disease onset in HAM/TSP 
(Figure  4B), rendering Fas as a clinically relevant molecule. It 
should be stated, however, that formal demonstration of the pos-
sible clinical utility of Fas expression or Fas downstream signaling 
targets as biomarker(s) in HAM/TSP will require confirmation 
of our findings in prospective cohort studies with a long-term 
clinical follow-up. In addition, agonist anti-Fas mAb, although 
restoring the defect in apoptosis in HAM/TSP, would not be a 
therapeutic option given that anti-Fas mAb therapy caused liver 
injury and lethality in mice (36). In the absence of clinical ben-
efit of antiretrovirals in HAM/TSP, immunomodulatory options 
include IFN-α/β, glucocorticoids, cyclosporine, and ascorbic acid 
(32, 37, 38). We previously demonstrated that IFN-β can restore 
defective B cell CD86 upregulation in HAM/TSP (29). As in MS, 
defective Fas-mediated apoptosis in HAM/TSP patients may be 
overcome by IFN-β therapy (39, 40). In addition to IFN therapy, 
our in  silico analysis might reveal novel treatment options. As 
shown in Figure 7B, a molecular network that elegantly describes 
the interplay between the molecular players of apoptosis (CARD6, 
caspases), proliferation (POLR2D, L3MBTL2), and inflammation 
(TNF, JNK), with a central role for NFκB. Therefore, our data 
confirm and extend the findings of Oh et al. (11) and Talledo et al. 
(9) who pointed at the importance of NFκB signaling in HAM/
TSP from a pharmacological and immunogenetic perspective. 
Furthermore, our Fas-triggered gene expression in HAM/TSP 
reveals the same upstream regulator (Rel A), which is associated 
to active disease in MS (35). Thus, transcriptomics can reveal 
neuroinflammatory disorders sharing analogous biological path-
ways, indicating approved MS drugs to be considered in HAM/
TSP, but also allow the identification of possible novel therapeutic 
targets, e.g., TGM2 or L3MBTL2 (Figure 7B).
Regarding HAM/TSP pathogenesis, both genetic and environ-
mental triggers have been suggested (41). Interestingly, in a large 
cohort in the same endemic area (Salvador, Bahia), a city with 
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Afro-descendent demography, probable (but not definite) HAM/
TSP occurred in 31% of AC during 8-year follow-up (42), which 
suggests lifetime risk in this population is 10-fold higher than pre-
viously reported (41). As for environmental factors,  co-infection 
with gram-positive bacteria, as in infective dermatitis, has been 
shown to trigger early HAM/TSP in children from the same 
endemic area (43, 44). Concerning genetics, a single FAS -670 
polymorphism has been associated to both ATL (26) and HAM/
TSP (27) susceptibility. Since this polymorphism also determined 
CD4 T stem cell memory (Tscm) levels in a genome-wide twin 
study (Khouri et al., submitted), the proliferative, non-apoptotic 
Fashi cells in HAM/TSP are reminiscent of a Tscm phenotype 
(45), as outlined in Figure 8. However, since CD4 or CD8 Tscm 
represent only a minor subset of Fas+ lymphocytes (46), a Tscm 
origin of Fashi cells is not likely, considering the two-step increase 
we observed both ex vivo and in vitro (Figures 2A,B and 4A), first 
in AC and second in HAM/TSP.
Non-apoptotic Fas signaling toward proliferation has been 
previously demonstrated (47, 48), while tax gene expression 
and cell cycling, but not cell death, are selected during HTLV-1 
infection in  vivo (49). Tax mediates its antiapoptotic activity 
by activating the NFκB pathway (50), associating NFκB to cell 
survival and inflammation, similar to our in  silico findings. In 
addition, Tax-deregulated autophagy and cFLIP expression are 
responsible for resistance to apoptosis in vitro (51), in agreement 
with our ex vivo and in vitro results. In contrast, many viral infec-
tions are associated with heightened apoptosis. The most striking 
example is HIV (52), which manipulates apoptotic pathways to 
enable efficient viral replication (53). In the case of HTLV-1, 
in  vitro culture triggers viral protein synthesis and subsequent 
cytokine-driven lymphoproliferation (14). However, Fas did not 
correlate to PVL, similar to (25) and two other published cohorts 
(p > 0.5 for test and training sets) (7). Interestingly, PVL also did 
not correlate to apoptosis or age of disease onset, in contrast to 
Fas. A previous larger study with sufficient statistical power also 
demonstrated PVL does not correlate to age of onset in HAM/
TSP (54). Furthermore, viral p19 protein levels did not correlate 
to Fas in our cohort. Taken together, increased Fas levels in HAM/
TSP appear to be driven by an IFN/STAT1 axis, either genetically 
(27) or environmentally (43) linked, rather than by the virus 
itself, suggesting that the role of Fas in HAM/TSP pathogenesis 
is independent of PVL. Therefore, it is tempting to speculate that 
a similar IFN/STAT1 signaling pathway might underlie the sug-
gested deleterious role of CD80+ B cells, correlating positively to 
disease severity, also independent of PVL (29).
In conclusion, our results suggest that defective Fas-mediated 
apoptosis is linked to early disease onset and might be an addi-
tional factor in HAM/TSP pathogenesis, independent of PVL. 
Triggering Fas signaling, rather than inhibiting it, induces a spe-
cific gene set with a central role for NFκB pro-survival signaling. 
Thus, our integrated ex vivo, in vitro, in silico approach identifies 
biased pro-inflammatory and proliferative Fas signaling in HAM/
TSP, revealing possible novel therapeutic targets.
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